Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis

Thromb Res. 2010 Jul;126(1):18-23. doi: 10.1016/j.thromres.2009.12.008. Epub 2010 Jan 18.

Abstract

Background: The diagnostic performance of modified criteria for non-overt disseminated intravascular coagulation (DIC) with the addition of antithrombin (AT) levels, protein C (PC) levels, and organ system failure scoring (OSF) to the International Society on Thrombosis and Hemostasis (ISTH) criteria for non-overt DIC was studied to determine the effect on predicting poor outcome in patients with sepsis.

Methods: In total, 135 consecutive patients were studied. Hemostatic markers (platelet count, prothrombin time, D-dimer, AT, PC) were examined on days 0, 1, 2, 3, 4, and 7. ISTH overt and non-overt DIC scoring, OSF, and 28-day mortality were analyzed.

Results: The numbers of patients with overt DIC, non-overt DIC and non-DIC were 42, 17 and 76 respectively. The 28-day mortality rates for ISTH overt DIC, ISTH non-overt DIC, and non-DIC were 47.6, 47.1, and 9.2%, respectively. By adding AT and PC to the ISTH non-overt DIC criteria, the 28-day mortality rate of overt DIC, non-overt DIC, and non-DIC changed to 47.6, 25.0, and 6.7%, respectively. By adding OSF to the ISTH non-overt DIC criteria to predict 28-day mortality in septic patients, receiver operating characteristic (ROC) curve analysis demonstrated that the area under the curve (AUC) of ISTH non-overt DIC (0.777) was significantly increased to 0.878 (P=0.018). However, neither AT nor PC increased the AUC.

Conclusions: Addition of OSF to the ISTH criteria for non-overt DIC gives a better prediction of poor outcome in patients with sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antithrombin III
  • Antithrombins
  • Disseminated Intravascular Coagulation / blood*
  • Disseminated Intravascular Coagulation / diagnosis*
  • Disseminated Intravascular Coagulation / mortality
  • Female
  • Fibrin Fibrinogen Degradation Products
  • Hemostasis
  • Humans
  • Male
  • Middle Aged
  • Platelet Count
  • Prognosis
  • Protein C
  • Prothrombin Time
  • ROC Curve
  • Sepsis / mortality
  • Thrombosis
  • Treatment Outcome

Substances

  • Antithrombins
  • Fibrin Fibrinogen Degradation Products
  • Protein C
  • fibrin fragment D
  • Antithrombin III